M&A Deal Summary |
|
|---|---|
| Date | 2021-02-01 |
| Target | Surgical Specialties |
| Sector | Medical Products |
| Buyer(s) | Corza Health |
| Sellers(s) | Vivo Capital |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2019 |
| Sector | Healthcare Services |
Corza Health makes investments in healthcare companies to help accelerate growth. Corza Health invest into high-caliber teams and provides appropriate relationships, learnings and support to create industry-leading brands, products and services. Corza Health was founded in 2019 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 4 |
| Sector (Medical Products) | 2 of 4 |
| Type (Add-on Acquisition) | 1 of 3 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 1 of 3 |
| Year (2021) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-16 |
TachoSil
Osaka, Japan TachoSil provides surgical patches used for bleeding control. |
Buy | $564M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-02 |
Katena
Parsippany, New Jersey, United States Katena is a provider of precision ophthalmic instruments and therapeutics to physician offices, hospitals, and surgical centers. Katena’s product offering includes precision surgical instruments, single-use devices, and specialty biologics that are sold into over 100 countries through a network of direct salespeople and distributors. Katena was founded in 1975 and is based in Parsippany, New Jersey. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 6.4B USD |
| Size | Mega |
| Type | Sector Focused |
Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1997 and is headquartered in Palo Alto, California.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 12 |
| Sector (Medical Products) | 3 of 3 |
| Type (Add-on Acquisition) | 2 of 3 |
| State (Massachusetts) | 3 of 3 |
| Country (United States) | 9 of 11 |
| Year (2021) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-13 |
IO Biotech
Copenhagen, Denmark IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. Our pipeline of first-in-class immune modulating anti-cancer therapies is based on a unique platform technology enabling the activation of T cells that are specific for immune inhibitory molecules. IO Biotech was founded in 2015 and is based in Copenhagen, Denmark. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-22 |
Impel NeuroPharma
Seattle, Washington, United States Impel NeuroPharma is a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for people suffering from diseases with high unmet needs, with an initial focus on diseases of the CNS. The Company’s strategy is to rapidly advance its product candidate pipeline that pairs its proprietary Precision Olfactory Delivery (POD) system with well-established therapeutics, including TRUDHESA for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. Impel NeuroPharma was formed in 2008 and is based in Seattle, Washington. |
Sell | - |
